Parexel experts and collaborators will present research exploring emerging clinical and operational considerations shaping obesity drug development. Explore Parexel’s accepted Obesity Week 2026 abstracts and connect with our experts to learn more about the research and its implications for obesity clinical development.
Visit Parexel at booth #115 to learn more.
Obesity week 2026 posters
GLP-1 treatment and safety
Oral Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Obesity: Expanding Use or a New Option for Existing Patients
Patrick Symmonds, PharmD, Vice President, Health Advances
Shipra Patel, MD, MS, Executive Director, Therapeutic Area Lead, Parexel
Presenter: Patrick Symmonds
Vision-Threatening Ocular Safety of GLP-1 Receptor Agonists: A Propensity-Matched Study
Kausik Maiti, MD, Vice President, Safety Medical Sciences, Parexel International
Shipra Patel, MD, MS, Executive Director, Therapeutic Area Lead, Parexel
Presenter: Shipra Patel
Early phase obesity clinical development
Operational Excellence in Early Phase Obesity Trials: Insights from Studies on Protocol Optimization, Participant Retention, Acceleration and Timeline
Dikshya Shrestha, PharmD, MBA, Senior Director, Pharmaceutical and Medical Services, Early Phase, Parexel
Ally Hohman, Associate Manager, Enrollment, Early Phase, Parexel
Presenter: Dikshya Shrestha
Healthy Obese Is Not a Traditional Healthy Volunteer: Considerations in Early Obesity Drug Trials
Dikshya Shrestha, PharmD, MBA, Senior Director, Pharmaceutical and Medical Services, Early Phase, Parexel
Rainard Fuhr, Senior Director, Clinical Pharmacology & Medical Services, Early Phase, Parexel
Presenter: Dikshya Shrestha